low - Pre-revenue biotech with minimal direct GDP linkage. Clinical trial timelines and regulatory processes are largely insulated from economic cycles. However, severe recessions can impact: (1) pharma partners' willingness to sign new licensing deals or advance programs, (2) capital markets access for equity financing, and (3) M&A valuations if REGENXBIO becomes a takeout target. Patient enrollment can be affected by healthcare system stress during economic downturns.

Rising interest rates create significant headwinds for pre-revenue biotech through multiple channels: (1) higher discount rates compress NPV of future cash flows 5-10+ years out, directly impacting valuation multiples, (2) reduced investor risk appetite shifts capital away from speculative growth stocks toward safer yielding alternatives, (3) increased cost of capital for future debt financing if needed. The company's 2.38x current ratio provides liquidity buffer, but sustained rate increases typically correlate with 20-40% biotech sector multiple compression. Cash holdings (~$200M estimated) earn higher yields in rising rate environment, partially offsetting negative valuation impact.

growth - High-risk, high-reward binary outcome profile attracts speculative growth investors and biotech specialists willing to underwrite clinical and regulatory risk for potential 3-5x returns on successful drug approval. The -95% operating margin and negative cash flow eliminate value and income investors. Recent 36% one-year return followed by -34% three-month decline demonstrates extreme volatility typical of clinical-stage names. Institutional ownership likely dominated by healthcare-focused hedge funds and venture capital rather than broad index funds. Momentum traders enter around data catalysts but lack sustained conviction.